WO2014191518A1 - A method for producing precise dna cleavage using cas9 nickase activity - Google Patents
A method for producing precise dna cleavage using cas9 nickase activity Download PDFInfo
- Publication number
- WO2014191518A1 WO2014191518A1 PCT/EP2014/061178 EP2014061178W WO2014191518A1 WO 2014191518 A1 WO2014191518 A1 WO 2014191518A1 EP 2014061178 W EP2014061178 W EP 2014061178W WO 2014191518 A1 WO2014191518 A1 WO 2014191518A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- sequence
- cell
- cas9
- sequences
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
- C12N15/8213—Targeted insertion of genes into the plant genome by homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
- C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
Definitions
- the present invention relates to a method of genome engineering based on the type II CRISPR system.
- the invention relates to a method for precisely inducing a nucleic acid cleavage in a genetic sequence of interest and preventing off-site cleavage.
- the method is based on the use of nickase architectures of Cas9 and single or multiple crRNA(s) harboring two different targets lowering the risk of producing off-site cleavage.
- the present invention also relates to polypeptides, polynucleotides, vectors, compositions, therapeutic applications related to the method described here.
- Site-specific nucleases are powerful reagents for specifically and efficiently targeting and modifying a DNA sequence within a complex genome.
- genome engineering by site-specific nucleases extending from basic research to bioindustrial applications and human therapeutics.
- Re-engineering a DNA-binding protein for this purpose has been mainly limited to the design and production of proteins such as the naturally occurring LADLIDADG homing endonucleases (LHE), artificial zinc finger proteins (ZFP), and Transcription Activator-Like Effectors nucleases (TALE-nucleases).
- LHE LADLIDADG homing endonucleases
- ZFP artificial zinc finger proteins
- TALE-nucleases Transcription Activator-Like Effectors nucleases
- Recently, a new genome engineering tool has been developed based on the RNA-guided Cas9 nuclease (Gasiunas, Barrangou et al.
- CRISPR Clustered Regularly Interspaced Short palindromic Repeats
- the CRISPR Associated (Cas) system was first discovered in bacteria and functions as a defense against foreign DNA, either viral or plasmid. So far three distinct bacterial CRISPR systems have been identified, termed type I, II and III. The Type II system is the basis for the current genome engineering technology available and is often simply referred to as CRISPR.
- the type II CRISPR/Cas loci are composed of an operon of genes encoding generally the proteins Cas9, Casl, Cas2 and Csn2a, Csn2bor Cas4 (Chylinski, Le Rhun et al. 2013), a CRISPR array consisting of a leader sequence followed by identical repeats interspersed with unique genome-targeting spacers and a sequence encoding the trans-activating tracrRNA.
- CRISPR-mediated adaptative immunity proceeds in three distinct stages: acquisition of foreign DNA, CRISPR RNA (crRNA) biogenesis and target interference, (see review (Sorek, Lawrence et al. 2013)).
- CRISPR/Cas machinery appears to target specific sequence for integration into the CRISPR locus. Sequences in foreign DNA selected for integration are called spacers and these sequences are often flanked by a short sequence motif, referred as the proto-spacer adjacent motif (PAM).
- PAM proto-spacer adjacent motif
- crRNA biogenesis in type II systems is unique in that it requires a trans-activating crRNA (tracRNA).
- CRISPR locus is initially transcribed as long precursor crRNA (pre-crRNA) from a promoter sequence in the leader.
- pre-crRNA crRNA
- Cas9 acts as a molecular anchor facilitating the base pairing of tracRNA with pre-cRNA for subsequent recognition and cleavage of pre-cRNA repeats by the host RNase III (Deltcheva, Chylinski et al.
- tracrRNA remains paired to the crRNA and bound to the Cas9 protein.
- the dual tracrRNAxrRNA structure acts as guide RNA that directs the endonuclease Cas9 to the cognate target DNA (Jinek, Chylinski et al. 2012).
- Target recognition by the Cas9-tracrRNA:crRNA complex is initiated by scanning the invading DNA molecule for homology between the protospacer sequence in the target DNA and the spacer-derived sequence in the crRNA.
- DNA targeting requires the presence of a short motif adjacent to the protospacer (protospacer adjacent motif - PAM).
- Cas9 subsequently introduces a blunt double strand break 3 bases upstream of the PAM motif (Garneau, Dupuis et al. 2010).
- the large Cas9 protein contains two predicted nuclease domains, namely HNH (McrA-like) nuclease domain that is located in the middle of the protein and a splitted RuvC- like nuclease domain (RNase H fold) (Haft, Selengut et al. 2005; Makarova, Grishin et al. 2006).
- the HNH nuclease domain and the Ruv-C domain have been found to be essential for double strand cleavage activity.
- Prokaryote type II CRISPR system is capable of recognizing any potential target sequence of 12 to 20 nucleotides followed by a specific PAM motif on its 3'end.
- the specificity for target recognition relies on only 12 nucleic acids (Jiang, Bikard et al. 2013; Qi, Larson et al. 2013), which is enough for ensuring unique cleavage site prokaryotic genomes on a statistical basis, but which is critical for larger genomes, like in eukaryotic cells, where 12 nucleic acids sequences may be found several times. There is therefore a need to develop strategies for improving specificity and reducing potential off-site using type II CRISPR system.
- the inventors have investigated different modifications into type II CRISPR system for improving specificity and reducing potential off-site.
- using mutated version of Cas9 having nickase activity instead of cleavase activity, can be used to produce cleavage at a given DNA target and increase the specificity in the same time.
- the method is based on the simultaneous use of nickase architecture of Cas9 (RuvC domain and/or HNH domain) and sgRNA(s) harboring two different complementary sequence to specific targets lowering the risk of producing off-site cleavage.
- the requirement for specificity passes from 12 to 24 nucleotides and, in turn, the probability to find two alternative binding sites of Cas9 (different from the ones coded in the two sgRNA) at an efficient distance from each other to produce an off-site cleavage gets really low.
- the invention extends to the crRNA, tracrRNA and Cas mutants designed to perform this method and to the cells transfected with the resulting modified type II CRISPR system.
- FIG. 1 Schematic of the type II CRIPSR/Cas system mediated DNA double-strand break.
- Cas 9 is guided by a two-RNA structure, named guide RNA (gRNA) formed by crRNA and tracRNA to cleave double-stranded nucleic acid target (dsDNA).
- gRNA guide RNA
- Cas9 RuvC domain induces a nick event (arrow) in one strand in position +3bp (versus the 3'end) respect with the PAM location and the Cas9 HNH domain induces a nick event (arrow) in the other strand in position +3bp (versus the 5'end).
- the figure illustrates only one aspect of the CRISPR/Cas system mediated double-strand break.
- FIG. 2 Schematic of the new type II CRISPR/Cas system using a Cas9 nickase.
- A-B Two nucleic acid targets each comprising in one strand a PAM motif in the 3'-ends are selected within a genetic sequence of interest. The two nucleic acid targets are spaced by a distance "d".
- Cas9 harboring a non-functional RuvC or HNH domain (RuvC(-) (A-C) or (HNH(-) (B-D) respectively) is guided by two engineered gRNA each comprising a sequence complementary to at least 12 nucleotides adjacent to the complementary PAM motif of the first and second nucleic acid targets.
- A-B Each PAM motifs of the two targets are present in different strands.
- the Cas9 nickase induces a nick (arrow) in the different strands resulting in a double-strand break within the genetic sequence of interest. C-D. Each PAM motifs of the two targets are present in the same strand.
- the Cas9 nickase induces a nick in the same strand of the genetic sequence of interest, resulting in the deletion of a single-strand nucleic acid sequence between the two nick events.
- the figure illustrates only some aspects of the C ISP /Cas system using Cas9 nickase.
- Figure 3 Schematic of the new type II CRISPR/Cas system using two different Cas9 nickases.
- A-B Two nucleic acid targets comprising two different PAM motifs (PAMl and PAM2) in the 3'end are selected within a genetic sequence of interest. The two nucleic acid targets are spaced by a distance "d".
- a first Cas9 harboring a non-functional RuvC is guided by an engineered gRNA which comprises sequence complementary to at least 12 nucleotides adjacent to the first complementary PAM motif.
- a second Cas9 harboring a non-functional HNH domain is guided by a second engineered gRNA which comprises a sequence complementary to at least 12 nucleotides adjacent to the second complementary PAM motif.
- Each PAM motifs of the two targets are present in the different strands.
- the two Cas9 nickases induce two nicks (arrows) in the same strand of the genetic sequence of interest, resulting in the deletion of a single-strand nucleic acid sequence between the two nick events.
- Each PAM motifs of the two targets are present in the same strand.
- the Cas9 nickases induce two nick events (arrows) in the different strands resulting in a double-strand break within the genetic sequence of interest.
- the figure illustrates only some aspects of the CRISPR/Cas system using Cas9 nickase.
- the present invention thus relates to a new method based on the CRISPR/Cas system to precisely induce a cleavage in a double-stranded nucleic acid target.
- This method derives from the genome engineering CRISPR adaptive immune system tool that has been developed based on the RNA- guided Cas9 nuclease (Gasiunas, Barrangou et al. 2012; Jinek, Chylinski et al. 2012).
- the present invention relates to a method for precisely inducing nucleic acid cleavage in a genetic sequence in a cell comprising one of several of the following steps:
- each nucleic acid targets comprising, on one strand, a PAM motif at one 3' extremities;
- each Cas9-tracrRNA:crRNA complex induces a nick event in double-stranded nucleic acid targets in order to cleave the genetic sequence between said nucleic acid targets.
- Cas9 also named Csnl (COG3513 - SEQ ID NO: 1) is a large protein that participates in both crRNA biogenesis and in the destruction of invading DNA. Cas9 has been described in different bacterial species such as S. thermophilus (Sapranauskas, Gasiunas et al. 2011), listeria innocua (Gasiunas, Barrangou et al. 2012; Jinek, Chylinski et al. 2012) and S.
- the large Cas9 protein contains two predicted nuclease domains, namely HNH (McrA-like) nuclease domain that is located in the middle of the protein and a splitted RuvC-like nuclease domain (RNase H fold) (Haft, Selengut et al. 2005; Makarova, Grishin et al. 2006).
- HNH motif is characteristic of many nucleases that act on double-stranded DNA including colicins, restriction enzymes and homing endonucleases.
- the domain HNH (SMART ID: SM00507, SCOP nomenclature:HNH family) is associated with a range of DNA binding proteins, performing a variety of binding and cutting functions (Gorbalenya 1994; Shub, Goodrich-Blair et al. 1994).
- Several of the proteins are hypothetical or putative proteins of no well-defined function.
- the ones with known function are involved in a range of cellular processes including bacterial toxicity, homing functions in groups I and II introns and inteins, recombination, developmental ⁇ controlled DNA rearrangement, phage packaging, and restriction endonuclease activity (Dalgaard, Klar et al. 1997). These proteins are found in viruses, archaebacteria, eubacteria, and eukaryotes.
- the HNH motif is often associated with endonuclease domains of self-propagating elements like inteins, Group I, and Group II introns (Gorbalenya 1994; Dalgaard, Klar et al. 1997).
- the HNH domain can be characterized by the presence of a conserved Asp/His residue flanked by conserved His (amino-terminal) and His/Asp/Glu (carboxy-terminal) residues at some distance.
- a substantial number of these proteins can also have a CX2C motif on either side of the central Asp/His residue.
- the HNH motif appears as a central hairpin of twisted ⁇ -strands, which are flanked on each side by an a helix (Kleanthous, Kuhlmann et al. 1999).
- the other CRISPR catalytic domain RuvC like RNaseH (also named RuvC) is found in proteins that show wide spectra of nucleolytic functions, acting both on RNA and DNA (RNaseH, RuvC, DNA transposases and retroviral integrases and PIWI domain of Argonaut proteins).
- HNH domain is responsible for nicking of one strand of the target double-stranded DNA and the RuvC-like RNaseH fold domain is involved in nicking of the other strand (comprising the PAM motif) of the double-stranded nucleic acid target (Jinek, Chylinski et al. 2012).
- these two domains result in blunt cleavage of the invasive DNA within the same target sequence (proto-spacer) in the immediate vicinity of the PAM (Jinek, Chylinski et al. 2012).
- Cas 9 is a nickase and induces a nick event within different target sequences.
- Cas9 can comprise mutation(s) in the catalytic residues of either the HNH or RuvC-like domains, to induce a nick event within different target sequences.
- the catalytic residues of the compact Cas9 protein are those corresponding to amino acids D10, D31, H840, H868, N882 and N891 of SEQ ID NO: 1 or aligned positions using CLUSTALW method on homologues of Cas Family members. Any of these residues can be replaced by any other amino acids, preferably by alanine residue.
- Mutation in the catalytic residues means either substitution by another amino acids, or deletion or addition of amino acids that induce the inactivation of at least one of the catalytic domain of cas9.
- Cas9 may comprise one or several of the above mutations. In another particular embodiment, Cas9 may comprise only one of the two RuvC and HNH catalytic domains.
- Cas9 of different species, Cas9 homologues, Cas9 engineered and functional variant thereof can be used. The invention envisions the use of such Cas9 variants to perform nucleic acid cleavage in a genetic sequence of interest.
- Said Cas9 variants have an amino acid sequence sharing at least 70 %, preferably at least 80 %, more preferably at least 90%, and even more preferably 95 % identity with Cas9 of different species, Cas9 homologues, Cas9 engineered and functional variant thereof.
- said Cas9 variants have an amino acid sequence sharing at least 70 %, preferably at least 80 %, more preferably at least 90%, and even more preferably 95 % identity with SEQ ID NO: 1.
- NHEJ non-homologous end joining
- one aspect of the present invention is to induce knock-outs or to introduce exogenous genetic sequences by homologous recombination into specific genetic loci.
- genetic sequence of interest any endogenous nucleic acid sequence, such as, for example a gene or a non-coding sequence within or adjacent to a gene, in which it is desirable modify by targeted cleavage and/or targeted homologous recombination.
- the sequence of interest can be present in a chromosome, an episome, an organellar genome such as mitochondrial or chloroplast genome or genetic material that can exist independently to the main body of genetic material such as an infecting viral genome, plasmids, episomes, transposons for example.
- a sequence of interest can be within the coding sequence of a gene, within transcribed non-coding sequence such as, for example, leader sequences, trailer sequence or introns, or within non-transcribed sequence, either upstream or downstream of the coding sequence.
- the first and the second double-stranded nucleic acid targets are comprised within the genetic sequence of interest into which it is desired to introduce a cleavage and thus genetic modification. Said modification may be a deletion of the genetic material, insertion of nucleotides in the genetic material or a combination of both deletion and insertion of nucleotides.
- target nucleic acid sequence By “target nucleic acid sequence” , “double-stranded nucleic acid target” or “DNA target” is intended a polynucleotide that can be processed by the Cas9-tracr NA:cr NA complex according to the present invention.
- the double-stranded nucleic acid target sequence is defined by the 5' to 3' sequence of one strand of said target.
- the two targets can be spaced away each other from 1 to 500 nucleotides, preferably between 3 to 300 nucleotides, more preferably between 3 to 50 nucleotides, again more preferably between 1 to 20 nucleotides.
- any potential selected double-stranded DNA target in the present invention may have a specific sequence on its 3' end, named the protospacer adjacent motif or protospacer associated motif (PAM).
- the PAM is present in the strand of the nucleic acid target sequence which is not complementary to the crRNA.
- the proto-spacer adjacent motif (PAM) may correspond to 2 to 5 nucleotides starting immediately or in the vicinity of the proto-spacer at the 3'-end.
- the sequence and the location of the PAM motif recognized by specific Cas9 vary among the different systems.
- PAM motif can be for examples NNAGAA, NAG, NGG, NGGNG, AWG, CC, CCN, TCN, TTC as non limiting examples (Shah, Erdmann et al. 2013).
- the S. pyogenes system requires an NGG sequence, where N can be any nucleotides.
- S. thermophilus Type II systems require NGGNG (Horvath and Barrangou 2010) and NNAGAAW (Deveau, Barrangou et al. 2008), while different S. mutant systems tolerate NGG or NAA (van der Ploeg 2009).
- PAM is not restricted to the region adjacent to the proto- spacer but can also be part of the proto-spacer (Mojica, Diez-Villasenor et al. 2009).
- the Cas9 protein can be engineered to recognize a non-natural PAM motif.
- the selected target sequence may comprise a smaller or a larger PAM motif with any combinations of amino acids.
- the two PAM motifs of the two nucleic acid targets can be present on the same nucleic acid strand and thus the Cas9 nickase harboring a non-functional RuvC or HNH nuclease domain induces two nick events on the same strand ( Figures 2C and D).
- the resulting single-strand nucleic acid located between the first and the second nick can be deleted. This deletion may be repaired by NHEJ or homologous recombination mechanisms.
- the two PAM motifs of the two nucleic acid targets can be present on opposed nucleic acid strands and thus the Cas9 nickase harboring a non-functional RuvC or HNH nuclease domain induces two nick events on each strand of the genetic sequence of interest ( Figures 2A and B) resulting in a double strand break within the genetic sequence of interest.
- the method of the present invention used two Cas9 nickases, each one capable of recognizing different PAM motifs within the two nucleic acid targets.
- the first Cas9 is capable of recognizing the NGG PAM motif and the second Cas9 is capable of recognizing the NNAGAAW PAM motif.
- the present invention relates to a method comprising one or several of the following steps:
- each Cas9-tracrRNA:crRNA complex induces a nick event in the double-stranded nucleic acid target.
- S. pyogenes Cas9 lacking functional RuvC or HNH catalytic domain and S. thermophilus Cas9 lacking functional RuvC or HNH catalytic domain can be introduced into the cell to specifically recognize NGG PAM motif in the first target nucleic acid sequence and NNAGAAW PAM motif in the second target nucleic acid sequence respectively.
- the two distinct PAM motifs of the two nucleic acid targets can be present on the same nucleic acid strand and thus the Cas9 nickases harboring a non-functional RuvC or HNH nuclease domain induces two nick events on the same strand.
- the resulting single- strand nucleic acid located between the first and the second nick can be deleted.
- the two distinct PAM motifs of the two nucleic acid targets can be present on opposed nucleic acid strands and thus the Cas9 nickases harboring a non-functional RuvC-like or HNH nuclease domain induces two nick events on each strand of the genetic sequence of interest resulting in a double-strand break within the genetic sequence of interest.
- the first Cas9 nickase harbors a non-functional RuvC-like nuclease domain and the second Cas9 nickase harbors a non-functional HNH nuclease domain.
- the different PAM motifs of the two nucleic acid targets can be on the same strand, thus the two Cas9 nickases induce a nick event on each strand ( Figure 3A), resulting in a double-strand break within the genetic sequence of interest.
- the two PAM motifs can also be on opposed strands and thus the two Cas9 nickases induce a nick event on the same strand of the genetic sequence of interest ( Figure 3B).
- the resulting single-strand nucleic acid located between the first and the second nick can be deleted. This deletion may be repaired by NHEJ or homologous recombination mechanisms.
- the method of the present invention comprises engineering two crRNAs with distinct complementary regions to each nucleic acid target.
- the CRISPR targeting RNA (crRNA) targeting sequences are transcribed from DNA sequences known as protospacers.
- Protospacers are clustered in the bacterial genome in a group called a CRISPR array.
- the protospacers are short sequences of known foreign DNA separated by a short palindromic repeat and kept like a record against future encounters.
- the CRISPR array is transcribed and the RNA is processed to separate the individual recognition sequences between the repeats.
- the Spacer-containing CRISPR locus is transcribed in a long pre-crRNA.
- the processing of the CRISPR array transcript (pre-crRNA) into individual crRNAs is dependent on the presence of a trans-activating crRNA (tracrRNA) that has sequence complementary to the palindromic repeat.
- tracrRNA trans-activating crRNA
- the tracrRNA hybridizes to the repeat regions separating the spacers of the pre-crRNA, initiating dsRNA cleavage by endogenous RNase III, which is followed by a second cleavage event within each spacer by Cas9, producing mature crRNAs that remain associated with the tracrRNA and Cas9 and form the Cas9-tracrRNA:crRNA complex.
- Engineered crRNA with tracrRNA is capable of targeting a selected nucleic acid sequence, obviating the need of RNase III and the crRNA processing in general (Jinek, Chylinski et al. 2012).
- two crRNA are engineered to comprise distinct sequences complementary to a part of one strand of the two nucleic acid targets such that it is capable of targeting, preferably inducing a nick event in each nucleic acid targets.
- the two nucleic acid targets are spaced away each other from 1 to 300 bp, preferably from 3 to 250 bp, preferably from 3 to 200 bp, more preferably from 3 to 150 bp, 3 to lOObp, 3 to 50bp, 3 to 25 bp, 3 to 10 bp.
- crRNA sequence is complementary to a strand of nucleic acid target, this strand does not comprise the PAM motif at the 3'-end ( Figure 1).
- each crRNA comprises a sequence of 5 to 50 nucleotides, preferably 8 to 20 nucleotides, more preferably 12 to 20 nucleotides which is complementary to the target nucleic acid sequence.
- the crRNA is a sequence of at least 30 nucleotides which comprises at least 10 nucleotides, preferably 12 nucleotides complementary to the target nucleic acid sequence.
- each crRNA may comprise a complementary sequence followed by 4-10 nucleotides on the 5'end to improve the efficiency of targeting (Cong, Ran et al. 2013; Mali, Yang et al. 2013; Qi, Larson et al. 2013).
- the complementary sequence of the crRNA is followed in 3'-end by a nucleic acid sequences named repeat sequence or 3' extension sequence.
- the crRNA according to the present invention can also be modified to increase its stability of the secondary structure and/or its binding affinity for Cas9.
- the crRNA can comprise a 2', 3'-cyclic phosphate.
- the 2', 3'- cyclic phosphate terminus seems to be involved in many cellular processes i.e. tRNA splicing, endonucleolytic cleavage by several ribonucleases, in self-cleavage by RNA ribozyme and in response to various cellular stress including accumulation of unfolded protein in the endoplasmatic reticulum and oxidative stress (Schutz, Hesselberth et al. 2010).
- the present invention relates to the modified crRNA comprising a 2', 3'-cyclic phosphate, and the methods for genome engineering based on the CRISPR/cas system (Jinek, Chylinski et al. 2012; Cong, Ran et al. 2013; Mali, Yang et al. 2013) comprising using the modified crRNA.
- the crRNA can be engineered to recognize at least the two target nucleic acid sequences simultaneously.
- same crRNA comprises at least two sequences complementary to a portion of the two target nucleic acid sequences.
- said complementary sequences are spaced by a repeat sequence.
- Trans-activating CRISPR RNA are characterized by an anti- repeat sequence capable of base-pairing with at least a part of the 3' extension sequence of crRNA to form a tracrRNAxrRNA also named guide RNA (gRNA).
- TracrRNA comprises a sequence complementary to a region of the crRNA.
- a synthetic single guide RNA comprising a fusion of crRNA and tracrRNA that forms a hairpin that mimics the tracrRNA-crRNA complex (Cong, Ran et al. 2013; Mali, Yang et al. 2013) can be used to direct Cas9 endonuclease-mediated cleavage of target nucleic acid.
- This system has been shown to function in a variety of eukaryotic cells, including human, zebra fish and yeast.
- the sgRNA may comprise two distinct sequences complementary to a portion of the two target nucleic acid sequences, preferably spaced by a repeat sequence.
- the methods of the invention involve introducing crRNA, tracrRNA, sgRNA and Cas9 into a cell.
- crRNA, tracrRNA, sgRNA or Cas9 may be synthesized in situ in the cell as a result of the introduction of polynucleotide encoding RNA or polypeptides into the cell.
- the crRNA, tracRNA, sgRNA, Cas9 RNA or Cas9 polypeptides could be produced outside the cell and then introduced thereto.
- Methods for introducing a polynucleotide construct into bacteria, plants, fungi and animals are known in the art and including as non limiting examples stable transformation methods wherein the polynucleotide construct is integrated into the genome of the cell, transient transformation methods wherein the polynucleotide construct is not integrated into the genome of the cell and virus mediated methods.
- Said polynucleotides may be introduced into a cell by for example, recombinant viral vectors (e.g. retroviruses, adenoviruses), liposomes and the like.
- transient transformation methods include for example microinjection, electroporation or particle bombardment.
- Said polynucleotides may be included in vectors, more particularly plasmids or virus, in view of being expressed in prokaryotic or eukaryotic cells.
- the invention also concerns the polynucleotides, in particular DNA or RNA encoding the polypeptides and proteins previously described. These polynucleotides may be included in vectors, more particularly plasmids or virus, in view of being expressed in prokaryotic or eukaryotic cells.
- the present invention contemplates modification of the Cas9 polynucleotide sequence such that the codon usage is optimized for the organism in which it is being introduced.
- Cas9 polynucleotide sequence derived from the pyogenes or S. Thermophilus codon optimized for use in human is set forth in (Cong, Ran et al. 2013; Mali, Yang et al. 2013).
- the Cas9 polynucleotides according to the present invention can comprise at least one subcellular localization motif.
- a subcellular localization motif refers to a sequence that facilitates transporting or confining a protein to a defined subcellular location that includes at least one of the nucleus, cytoplasm, plasma membrane, endoplasmic reticulum, golgi apparatus, endosomes, peroxisomes and mitochondria.
- Subcellular localization motifs are well- known in the art.
- a subcellular localization motif requires a specific orientation, e.g., N- and/or C- terminal to the protein.
- the nuclear localization signal (NLS) of the simian virus 40 large T-antigen can be oriented at the N and/or C-terminus.
- NLS is an amino acid sequence which acts to target the protein to the cell nucleus through Nuclear Pore Complex and to direct a newly synthesized protein into the nucleus via its recognition by cytosolic nuclear transport receptors.
- a NLS consists of one or more short sequences of positively charged amino acids such as lysines or arginines.
- the present invention also relates to a method for modifying genetic sequence of interest further comprising the step of expressing an additional catalytic domain into a host cell.
- the present invention relates to a method to increase mutagenesis wherein said additional catalytic domain is a DNA end-processing enzyme.
- DNA end-processing enzymes include 5-3' exonucleases, 3-5' exonucleases, 5-3' alkaline exonucleases, 5' flap endonucleases, helicases, hosphatase, hydrolases and template- independent DNA polymerases.
- Non limiting examples of such catalytic domain comprise of a protein domain or catalytically active derivate of the protein domain seleced from the group consisting of hExol (EX01_HUMAN), Yeast Exol (EX01_YEAST), E.coli Exol, Human TREX2, Mouse TREX1, Human TREX1, Bovine TREX1, Rat TREX1, TdT (terminal deoxynucleotidyl transferase) Human DNA2, Yeast DNA2 (DNA2_YEAST).
- said additional catalytic domain has a 3'-5'-exonuclease activity, and in a more preferred embodiment, said additional catalytic domain has T EX exonuclease activity, more preferably TREX2 activity. In another preferred embodiment, said catalytic domain is encoded by a single chain TREX polypeptide.
- the present invention relates to a method for inducing homologous gene targeting in the genetic sequence of interest further comprising providing to the cell an exogeneous nucleic acid comprising at least a sequence homologous to a portion of the genetic sequence of interest, such that homologous recombination occurs between the genetic sequence of interest and the exogenous nucleic acid.
- said exogenous nucleic acid comprises first and second portions which are homologous to region 5' and 3' of the genetic sequence of interest respectively.
- Said exogenous nucleic acid in these embodiments also comprises a third portion positioned between the first and the second portion which comprises no homology with the regions 5' and 3' of the genetic sequence of interest.
- a homologous recombination event is stimulated between the target nucleic acid sequence and the exogenous nucleic acid.
- homologous sequences of at least 50 bp, preferably more than 100 bp and more preferably more than 200 bp are used within said exogenous nucleic acid. Therefore, the exogenous nucleic acid is preferably from 200 bp to 6000 bp, more preferably from 1000 bp to 2000 bp. Indeed, shared nucleic acid homologies are located in regions flanking upstream and downstream the cleavage induced and the nucleic acid sequence to be introduced should be located between the two arms.
- exogenous nucleic acid can be used to knock-out a gene, e.g. when exogenous nucleic acid is located within the open reading frame of said gene, or to introduce new sequences or genes of interest.
- Sequence insertions by using such exogenous nucleic acid can be used to modify a targeted existing gene, by correction or replacement of said gene (allele swap as a non-limiting example), or to up- or down-regulate the expression of the targeted gene (promoter swap as non- limiting example), said targeted gene correction or replacement.
- Cells can be any prokaryotic or eukaryotic living cells, cell lines derived from these organisms for in vitro cultures, primary cells from animal or plant origin.
- primary cell or “primary cells” are intended cells taken directly from living tissue (i.e. biopsy material) and established for growth in vitro, that have undergone very few population doublings and are therefore more representative of the main functional components and characteristics of tissues from which they are derived from, in comparison to continuous tumorigenic or artificially immortalized cell lines. These cells thus represent a more valuable model to the in vivo state they refer to.
- fungus refers to a fungal, plant, algal or animal cell or a cell line derived from the organisms listed below and established for in vitro culture. More preferably, the fungus is of the genus Aspergillus, Penicillium, Acremonium, Trichoderma, Chrysoporium, Mortierella, Kluyveromyces or Pichia; More preferably, the fungus is of the species Aspergillus niger, Aspergillus nidulans, Aspergillus oryzae, Aspergillus terreus, Penicillium chrysogenum, Penicillium citrinum, Acremonium Chrysogenum, Trichoderma reesei, Mortierella alpine, Chrysosporium lucknowense, Kluyveromyceslactis, Pichia pastoris or Pichia ciferrii.
- the plant is of the genus Arabidospis, Nicotiana, Solanum, lactuca, Brassica, Oryza, Asparagus, Pisum, Medicago, Zea, Hordeum, Secale, Triticum, Capsicum, Cucumis, Cucurbita, Citrullis, Citrus, Sorghum; More preferably, the plant is of the species Arabidospis thaliana, Nicotiana tabaccum, Solanum lycopersicum, Solanum tuberosum, Solanum melongena, Solanum esculentum, Lactuca saliva, Brassica napus, Brassica oleracea, Brassica rapa, Oryza glaberrima, Oryza sativa, Asparagus officinalis, Pisumsativum, Medicago sativa, zea mays, Hordeum vulgare, Secale cereal, Triticuma estivum, Triticum durum, Capsicum sativus, Cucur
- the animal cell is of the genus Homo, Rattus, Mus, Sus, Bos, Danio, Canis, Felis, Equus, Salmo, Oncorhynchus, Gallus, Meleagris, Drosophila, Caenorhabditis; more preferably, the animal cell is of the species Homo sapiens, Rattus norvegicus, Mus musculus, Sus scrofa, Bos taurus, Danio rerio, Canis lupus, Felis catus, Equus caballus, Salmo salar, Oncorhynchus mykiss, Gallus gallus, Meleagris gallopavo, Drosophila melanogaster, Caenorhabditis elegans.
- the cell is preferably a plant cell, a mammalian cell, a fish cell, an insect cell or cell lines derived from these organisms for in vitro cultures or primary cells taken directly from living tissue and established for in vitro culture.
- cell lines can be selected from the group consisting of CHO-K1 cells; HEK293 cells; Caco2 cells; U2-OS cells; NIH 3T3 cells; NSO cells; SP2 cells; CHO-S cells; DG44 cells; K-562 cells, U-937 cells; M C5 cells; IMR90 cells; Jurkat cells; HepG2 cells; HeLa cells; HT-1080 cells; HCT-116 cells; Hu-h7 cells; Huvec cells; Molt 4 cells.
- stem cells embryonic stem cells and induced Pluripotent Stem cells (iPS).
- All these cell lines can be modified by the method of the present invention to provide cell line models to produce, express, quantify, detect, study a gene or a protein of interest; these models can also be used to screen biologically active molecules of interest in research and production and various fields such as chemical, biofuels, therapeutics and agronomy as non-limiting examples.
- a particular aspect of the present invention relates to an isolated cell as previously described obtained by the method according to the invention.
- said isolated cell comprises Cas9 nickases, crRNA(s) and tracrRNA or sgRNA.
- Resulting isolated cell comprises a modified genetic sequence of interest in which a cleavage has occurred.
- the resulting modified cell can be used as a cell line for a diversity of applications ranging from bioproduction, animal transgenesis (by using for instance stem cells), plant transgenesis (by using for instance protoplasts), to cell therapy (by using for instance T-cells).
- the methods of the invention are useful to engineer genomes and to reprogram cells, especially iPS cells and ES cells.
- Another aspect of the invention is a kit for cell transformation comprising one or several of the components of the modified type II CRISPR system according to the invention as previously described.
- This kit more particularly comprises: - two crRNAs comprising a sequence complementary to one strand of a first and second double-strand nucleic acid target sequences comprising PAM motif in the other strand and having a 3' extension sequence ; at least one tracrRNA comprising a sequence complementary to the 3' extension sequences of said crRNAs; - at least one cas9 nuclease harboring a non-functional RuvC-like or HNH nuclease domain or a polynucleotide encoding thereof.
- the kit comprises:
- Two crRNAs comprising a sequence complementary to one strand of a first and second double-strand nucleic acid target sequences comprising different PAM motifs in the other strand and having a 3'extension sequence; at least one tracr NA comprising a sequence complementary to the 3' extension sequences of said crRNAs; a first Cas9 nuclease specifically recognizing the PAM motif of the first nucleic acid target and harboring a non-functional RuvC-like or a polynucleotide encoding thereof.
- a second Cas9 nuclease specifically recognizing the PAM motif of the second nucleic acid target and harboring a non-functional HNH nuclease domain or a polynucleotide encoding thereof.
- the present invention also encompasses transgenic animals or plants which comprises modified targeted genetic sequence of interest by the methods described above.
- Animals may be generated by methods described above into a cell or an embryo.
- the present invention relates to a method for generating an animal, comprising providing an eukaryotic cell comprising a genetic sequence of interest into which it is desired to introduce a genetic modification; generating a cleavage within the genetic sequence of interest by any one of the methods according to the present invention; and generating an animal from the cell or progeny thereof, in which cleavage has occurred.
- the embryo is a fertilized one cell stage embryo.
- Components of the method may be introduced into the cell by any of the methods known in the art including micro injection into the nucleus or cytoplasm of the embryo.
- the method for generating an animal further comprise introducing an exogenous nucleic acid as desired.
- the exogenous nucleic acid can include for example a nucleic acid sequence that disrupts a gene after homologous recombination, a nucleic acid sequence that replaces a gene after homologous recombination, a nucleic acid sequence that introduces a mutation into a gene after homologous recombination or a nucleic acid sequence that introduce a regulatory site after homologous recombination.
- the embryos are then cultures to develop an animal.
- an animal in which at least a genetic sequence of interest has been engineered is provided.
- an engineered gene may become inactivated such that it is not transcribed or properly translated, or an alternate form of the gene is expressed.
- the animal may be homozygous or heterozygous for the engineered gene.
- the present invention also related to a method for generating a plant comprising providing a plant cell comprising a genetic sequence of interest into which it is desired to introduce a genetic modification; generating a cleavage within the genetic sequence of interest by any one of the methods according to the present invention; and generating a plant from the cell or progeny thereof, in which cleavage has occurred.
- Progeny includes descendants of a particular plant or plant line.
- the method for generating a plant further comprise introducing an exogenous nucleic acid as desired.
- Plant cells produced using methods can be grown to generate plants having in their genome a modified genetic locus of interest. Seeds from such plants can be used to generate plants having a phenotype such as, for example, an altered growth characteristic, altered appearance, or altered compositions with respect to unmodified plants.
- the method disclosed herein can have a variety of applications.
- the method can be used for clinical or therapeutic applications.
- the method can be used to repair or correct disease-causing genes, as for example a single nucleotide change in sickle-cell disease.
- the method can be used to correct splice junction mutations, deletions, insertions, and the like in other genes or chromosomal sequences that play a role in a particular disease or disease state.
- Such methods can also be used to genetically modify iPS or primary cells, for instance T-cells, in view of injected such cells into a patient for treating a disease or infection.
- Such cell therapy schemes are more particularly developed for treating cancer, viral infection such as caused by CMV or HIV or self-immune diseases.
- Amino acid residues in a polypeptide sequence are designated herein according to the one-letter code, in which, for example, Q means Gin or Glutamine residue, means Arg or Arginine residue and D means Asp or Aspartic acid residue.
- Amino acid substitution means the replacement of one amino acid residue with another, for instance the replacement of an Arginine residue with a Glutamine residue in a peptide sequence is an amino acid substitution.
- Nucleotides are designated as follows: one-letter code is used for designating the base of a nucleoside: a is adenine, t is thymine, c is cytosine, and g is guanine.
- r represents g or a (purine nucleotides)
- k represents g or t
- s represents g or c
- w represents a or t
- m represents a or c
- y represents t or c (pyrimidine nucleotides)
- d represents g, a or t
- v represents g, a or c
- b represents g, t or c
- h represents a, t or c
- n represents g, a, t or c.
- nucleic acid or polynucleotide refers to nucleotides and/or polynucleotides, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), oligonucleotides, fragments generated by the polymerase chain reaction (PCR), and fragments generated by any of ligation, scission, endonuclease action, and exonuclease action.
- DNA deoxyribonucleic acid
- RNA ribonucleic acid
- PCR polymerase chain reaction
- Nucleic acid molecules can be composed of monomers that are naturally-occurring nucleotides (such as DNA and RNA), or analogs of naturally-occurring nucleotides (e.g., enantiomeric forms of naturally-occurring nucleotides), or a combination of both.
- Modified nucleotides can have alterations in sugar moieties and/or in pyrimidine or purine base moieties.
- Sugar modifications include, for example, replacement of one or more hydroxyl groups with halogens, alkyl groups, amines, and azido groups, or sugars can be functionalized as ethers or esters.
- sugar moiety can be replaced with sterically and electronically similar structures, such as aza-sugars and carbocyclic sugar analogs.
- modifications in a base moiety include alkylated purines and pyrimidines, acylated purines or pyrimidines, or other well-known heterocyclic substitutes.
- Nucleic acid monomers can be linked by phosphodiester bonds or analogs of such linkages. Nucleic acids can be either single stranded or double stranded.
- complementary sequence is meant the sequence part of polynucleotide (e.g. part of crRNa or tracRNA) that can hybridize to another part of polynucleotides (e.g. the target nucleic acid sequence or the crRNA respectively) under standard low stringent conditions.
- Such conditions can be for instance at room temperature for 2 hours by using a buffer containing 25% formamide, 4x SSC, 50 mM NaH2P04 / Na2HP04 buffer; pH 7.0,5x Denhardt's, 1 mM EDTA,1 mg/ml DNA + 20 to 200 ng/ml probe to be tested (approx. 20 - 200 ng/ml)).
- sequences are complementary to each other pursuant to the complementarity between two nucleic acid strands relying on Watson-Crick base pairing between the strands, i.e. the inherent base pairing between adenine and thymine (A-T) nucleotides and guanine and cytosine (G-C) nucleotides.
- A-T adenine and thymine
- G-C guanine and cytosine
- Accurate base pairing equates with Watson-Crick base pairing includes base pairing between standard and modified nucleosides and base pairing between modified nucleosides, where the modified nucleosides are capable of substituting for the appropriate standard nucleosides according to the Watson-Crick pairing.
- the complementary sequence of the single- strand oligonucleotide can be any length that supports specific and stable hybridization between the two single-strand oligonucleotides under the reaction conditions.
- the complementary sequence generally authorizes a partial double stranded overlap between the two hybridized oligonucleotides over more than 3bp, preferably more than 5 bp, preferably more than to 10 bp.
- nucleic acid homologous sequence it is meant a nucleic acid sequence with enough identity to another one to lead to homologous recombination between sequences, more particularly having at least 80% identity, preferably at least 90% identity and more preferably at least 95%, and even more preferably 98 % identity.
- Identity refers to sequence identity between two nucleic acid molecules or polypeptides. Identity can be determined by comparing a position in each sequence which may be aligned for purposes of comparison.
- nucleic acid or amino acid sequences When a position in the compared sequence is occupied by the same base, then the molecules are identical at that position.
- a degree of similarity or identity between nucleic acid or amino acid sequences is a function of the number of identical or matching nucleotides at positions shared by the nucleic acid sequences.
- Various alignment algorithms and/or programs may be used to calculate the identity between two sequences, including FASTA, or BLAST which are available as a part of the GCG sequence analysis package (University of Wisconsin, Madison, Wis.), and can be used with, e.g., default setting.
- vector refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
- a “vector” in the present invention includes, but is not limited to, a viral vector, a plasmid, a NA vector or a linear or circular DNA or RNA molecule which may consists of a chromosomal, non-chromosomal, semi-synthetic or synthetic nucleic acids.
- Preferred vectors are those capable of autonomous replication (episomal vector) and/or expression of nucleic acids to which they are linked (expression vectors). Large numbers of suitable vectors are known to those of skill in the art and commercially available.
- Viral vectors include retrovirus, adenovirus, parvovirus (e. g. adenoassociated viruses), coronavirus, negative strand RNA viruses such as orthomyxovirus (e. g., influenza virus), rhabdovirus (e. g., rabies and vesicular stomatitis virus), paramyxovirus (e. g. measles and Sendai), positive strand RNA viruses such as picornavirus and alphavirus, and double-stranded DNA viruses including adenovirus, herpesvirus (e. g., Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxvirus (e.
- orthomyxovirus e. g., influenza virus
- rhabdovirus e. g., rabies and vesicular stomatitis virus
- paramyxovirus e. g. measles and Sendai
- viruses include Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, and hepatitis virus, for example.
- retroviruses include: avian leukosis-sarcoma, mammalian C-type, B-type viruses, D type viruses, HTLV-BLV group, lentivirus, spumavirus (Coffin, J. M., etroviridae: The viruses and their replication, In Fundamental Virology, Third Edition, B. N. Fields, et al., Eds., Lippincott-Raven Publishers, Philadelphia, 1996).
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2014273082A AU2014273082B2 (en) | 2013-05-29 | 2014-05-28 | A method for producing precise DNA cleavage using Cas9 nickase activity |
EP14727479.9A EP3004349B1 (en) | 2013-05-29 | 2014-05-28 | A method for producing precise dna cleavage using cas9 nickase activity |
US14/892,743 US20160122774A1 (en) | 2013-05-29 | 2014-05-28 | A method for producing precise dna cleavage using cas9 nickase activity |
DK14727479.9T DK3004349T3 (en) | 2013-05-29 | 2014-05-28 | A method for producing precise DNA cleavage using CAS9 nickase activity |
JP2016516169A JP7065564B2 (en) | 2013-05-29 | 2014-05-28 | Methods for Providing Accurate DNA Cleavage Using CAS9 Nickase Activity |
CA2913865A CA2913865C (en) | 2013-05-29 | 2014-05-28 | A method for producing precise dna cleavage using cas9 nickase activity |
ES14727479.9T ES2670531T3 (en) | 2013-05-29 | 2014-05-28 | A method to produce an accurate DNA cleavage using the nickase activity of Cas9 |
HK16111735.9A HK1223400A1 (en) | 2013-05-29 | 2016-10-11 | A method for producing precise dna cleavage using cas9 nickase activity cas9 dna |
US16/045,602 US20180327761A1 (en) | 2013-05-29 | 2018-07-25 | Method for producing precise dna cleavage using cas9 nickase activity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201370295 | 2013-05-29 | ||
DKPA201370295 | 2013-05-29 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/892,743 A-371-Of-International US20160122774A1 (en) | 2013-05-29 | 2014-05-28 | A method for producing precise dna cleavage using cas9 nickase activity |
US16/045,602 Continuation US20180327761A1 (en) | 2013-05-29 | 2018-07-25 | Method for producing precise dna cleavage using cas9 nickase activity |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014191518A1 true WO2014191518A1 (en) | 2014-12-04 |
Family
ID=48628223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2014/061178 WO2014191518A1 (en) | 2013-05-29 | 2014-05-28 | A method for producing precise dna cleavage using cas9 nickase activity |
Country Status (9)
Country | Link |
---|---|
US (2) | US20160122774A1 (en) |
EP (1) | EP3004349B1 (en) |
JP (2) | JP7065564B2 (en) |
AU (1) | AU2014273082B2 (en) |
CA (1) | CA2913865C (en) |
DK (1) | DK3004349T3 (en) |
ES (1) | ES2670531T3 (en) |
HK (1) | HK1223400A1 (en) |
WO (1) | WO2014191518A1 (en) |
Cited By (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9068179B1 (en) | 2013-12-12 | 2015-06-30 | President And Fellows Of Harvard College | Methods for correcting presenilin point mutations |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
WO2015159087A1 (en) * | 2014-04-17 | 2015-10-22 | Green Biologics Limited | Targeted mutations |
WO2015159086A1 (en) * | 2014-04-17 | 2015-10-22 | Green Biologics Limited | Deletion mutations |
US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US9322006B2 (en) | 2011-07-22 | 2016-04-26 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
JP2016521995A (en) * | 2013-06-17 | 2016-07-28 | ザ・ブロード・インスティテュート・インコーポレイテッド | Delivery, use and therapeutic applications of CRISPR-Cas systems and compositions for targeting disorders and diseases using viral components |
JP2016521993A (en) * | 2013-06-17 | 2016-07-28 | ザ・ブロード・インスティテュート・インコーポレイテッド | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
JP2016523082A (en) * | 2013-06-17 | 2016-08-08 | ザ・ブロード・インスティテュート・インコーポレイテッド | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of mitotic cells |
WO2016073990A3 (en) * | 2014-11-07 | 2016-08-11 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
JP2016524472A (en) * | 2013-06-17 | 2016-08-18 | ザ・ブロード・インスティテュート・インコーポレイテッド | Delivery and use of CRISPR-Cas systems, vectors and compositions for liver targeting and therapy |
US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US9546384B2 (en) | 2013-12-11 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a mouse genome |
WO2016154579A3 (en) * | 2015-03-26 | 2017-01-26 | Editas Medicine, Inc. | Crispr/cas-mediated gene conversion |
WO2017019867A1 (en) * | 2015-07-28 | 2017-02-02 | Danisco Us Inc | Genome editing systems and methods of use |
WO2017053879A1 (en) * | 2015-09-24 | 2017-03-30 | Editas Medicine, Inc. | Use of exonucleases to improve crispr/cas-mediated genome editing |
EP3003392A4 (en) * | 2013-06-04 | 2017-05-03 | President and Fellows of Harvard College | Rna-guideded transcriptional regulation |
US9663782B2 (en) | 2013-07-19 | 2017-05-30 | Larix Bioscience Llc | Methods and compositions for producing double allele knock outs |
WO2017118720A1 (en) * | 2016-01-08 | 2017-07-13 | Novozymes A/S | Genome editing in bacillus host cells |
EP3219799A1 (en) | 2016-03-17 | 2017-09-20 | IMBA-Institut für Molekulare Biotechnologie GmbH | Conditional crispr sgrna expression |
WO2017186718A1 (en) * | 2016-04-25 | 2017-11-02 | Universität Basel | Allele editing and applications thereof |
US9834791B2 (en) | 2013-11-07 | 2017-12-05 | Editas Medicine, Inc. | CRISPR-related methods and compositions with governing gRNAS |
JP2017537647A (en) * | 2014-12-16 | 2017-12-21 | ダニスコ・ユーエス・インク | Fungal genome modification system and method of use |
EP3167071A4 (en) * | 2014-07-09 | 2018-01-17 | Gen9, Inc. | Compositions and methods for site-directed dna nicking and cleaving |
EP3272867A1 (en) * | 2016-06-02 | 2018-01-24 | Sigma-Aldrich Co. LLC | Using programmable dna binding proteins to enhance targeted genome modification |
WO2018015444A1 (en) * | 2016-07-22 | 2018-01-25 | Novozymes A/S | Crispr-cas9 genome editing with multiple guide rnas in filamentous fungi |
US9888673B2 (en) | 2014-12-10 | 2018-02-13 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
WO2018054911A1 (en) | 2016-09-23 | 2018-03-29 | Bayer Cropscience Nv | Targeted genome optimization in plants |
WO2018083461A1 (en) * | 2016-11-01 | 2018-05-11 | Auxolytic Ltd | Regulatable cell lines and methods of use thereof |
US9970030B2 (en) | 2014-08-27 | 2018-05-15 | Caribou Biosciences, Inc. | Methods for increasing CAS9-mediated engineering efficiency |
EP2877571B1 (en) | 2013-09-18 | 2018-05-30 | Kymab Limited | Methods, cells and organisms |
JP2018515142A (en) * | 2015-05-15 | 2018-06-14 | ダーマコン,インコーポレイテッド. | Synthetic single guide RNA for CAS9-mediated gene editing |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US10081807B2 (en) | 2012-04-24 | 2018-09-25 | Gen9, Inc. | Methods for sorting nucleic acids and multiplexed preparative in vitro cloning |
JP2018530348A (en) * | 2015-10-06 | 2018-10-18 | インスティチュート フォー ベーシック サイエンスInstitute For Basic Science | A highly efficient method for producing genome-editing plants from plant protoplasts |
US10106820B2 (en) | 2014-06-06 | 2018-10-23 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for modifying a targeted locus |
US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US10136649B2 (en) | 2015-05-29 | 2018-11-27 | North Carolina State University | Methods for screening bacteria, archaea, algae, and yeast using CRISPR nucleic acids |
US10166255B2 (en) | 2015-07-31 | 2019-01-01 | Regents Of The University Of Minnesota | Intracellular genomic transplant and methods of therapy |
US10167457B2 (en) | 2015-10-23 | 2019-01-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
JP2019500899A (en) * | 2015-11-23 | 2019-01-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Cellular RNA tracking and manipulation through nuclear delivery of CRISPR / Cas9 |
US10202608B2 (en) | 2006-08-31 | 2019-02-12 | Gen9, Inc. | Iterative nucleic acid assembly using activation of vector-encoded traits |
EP3303634A4 (en) * | 2015-06-03 | 2019-03-20 | The Regents of The University of California | Cas9 variants and methods of use thereof |
US10308931B2 (en) | 2012-03-21 | 2019-06-04 | Gen9, Inc. | Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis |
US10337001B2 (en) | 2014-12-03 | 2019-07-02 | Agilent Technologies, Inc. | Guide RNA with chemical modifications |
WO2019138083A1 (en) | 2018-01-12 | 2019-07-18 | Basf Se | Gene underlying the number of spikelets per spike qtl in wheat on chromosome 7a |
US10385359B2 (en) | 2013-04-16 | 2019-08-20 | Regeneron Pharmaceuticals, Inc. | Targeted modification of rat genome |
US10428319B2 (en) | 2017-06-09 | 2019-10-01 | Editas Medicine, Inc. | Engineered Cas9 nucleases |
US10450584B2 (en) | 2014-08-28 | 2019-10-22 | North Carolina State University | Cas9 proteins and guiding features for DNA targeting and genome editing |
US10457935B2 (en) | 2010-11-12 | 2019-10-29 | Gen9, Inc. | Protein arrays and methods of using and making the same |
US10457960B2 (en) | 2014-11-21 | 2019-10-29 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification using paired guide RNAs |
WO2019217803A1 (en) | 2018-05-10 | 2019-11-14 | Auxolytic Ltd. | Gene therapy methods and compositions using auxotrophic regulatable cells |
US10494621B2 (en) | 2015-06-18 | 2019-12-03 | The Broad Institute, Inc. | Crispr enzyme mutations reducing off-target effects |
US10550372B2 (en) | 2013-12-12 | 2020-02-04 | The Broad Institute, Inc. | Systems, methods and compositions for sequence manipulation with optimized functional CRISPR-Cas systems |
US10584358B2 (en) | 2013-10-30 | 2020-03-10 | North Carolina State University | Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri |
US10640789B2 (en) | 2013-06-04 | 2020-05-05 | President And Fellows Of Harvard College | RNA-guided transcriptional regulation |
WO2020128478A1 (en) | 2018-12-19 | 2020-06-25 | King's College London | Immunotherapeutic methods and compositions |
US10696986B2 (en) | 2014-12-12 | 2020-06-30 | The Board Institute, Inc. | Protected guide RNAS (PGRNAS) |
US10711285B2 (en) | 2013-06-17 | 2020-07-14 | The Broad Institute, Inc. | Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation |
US10711267B2 (en) | 2018-10-01 | 2020-07-14 | North Carolina State University | Recombinant type I CRISPR-Cas system |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
US10781444B2 (en) | 2013-06-17 | 2020-09-22 | The Broad Institute, Inc. | Functional genomics using CRISPR-Cas systems, compositions, methods, screens and applications thereof |
US10787654B2 (en) | 2014-01-24 | 2020-09-29 | North Carolina State University | Methods and compositions for sequence guiding Cas9 targeting |
US10851357B2 (en) | 2013-12-12 | 2020-12-01 | The Broad Institute, Inc. | Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders |
US10912797B2 (en) | 2016-10-18 | 2021-02-09 | Intima Bioscience, Inc. | Tumor infiltrating lymphocytes and methods of therapy |
US10930367B2 (en) | 2012-12-12 | 2021-02-23 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for Cas enzymes or CRISPR-Cas systems for target sequences and conveying results thereof |
US11041173B2 (en) | 2012-12-12 | 2021-06-22 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
WO2021122080A1 (en) * | 2019-12-16 | 2021-06-24 | BASF Agricultural Solutions Seed US LLC | Improved genome editing using paired nickases |
US11072789B2 (en) | 2012-06-25 | 2021-07-27 | Gen9, Inc. | Methods for nucleic acid assembly and high throughput sequencing |
US11078483B1 (en) | 2016-09-02 | 2021-08-03 | KSQ Therapeutics, Inc. | Methods for measuring and improving CRISPR reagent function |
US11078481B1 (en) | 2016-08-03 | 2021-08-03 | KSQ Therapeutics, Inc. | Methods for screening for cancer targets |
US11084014B2 (en) | 2010-11-12 | 2021-08-10 | Gen9, Inc. | Methods and devices for nucleic acids synthesis |
US11098325B2 (en) | 2017-06-30 | 2021-08-24 | Intima Bioscience, Inc. | Adeno-associated viral vectors for gene therapy |
US11111521B2 (en) | 2011-12-22 | 2021-09-07 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11155795B2 (en) | 2013-12-12 | 2021-10-26 | The Broad Institute, Inc. | CRISPR-Cas systems, crystal structure and uses thereof |
US11155823B2 (en) | 2015-06-15 | 2021-10-26 | North Carolina State University | Methods and compositions for efficient delivery of nucleic acids and RNA-based antimicrobials |
US11186843B2 (en) | 2014-02-27 | 2021-11-30 | Monsanto Technology Llc | Compositions and methods for site directed genomic modification |
WO2021239758A1 (en) * | 2020-05-27 | 2021-12-02 | Snipr Biome Aps. | Multiplex crispr/cas system for modifying cell genomes |
US11236313B2 (en) | 2016-04-13 | 2022-02-01 | Editas Medicine, Inc. | Cas9 fusion molecules, gene editing systems, and methods of use thereof |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
US11286480B2 (en) | 2015-09-28 | 2022-03-29 | North Carolina State University | Methods and compositions for sequence specific antimicrobials |
US11299767B2 (en) | 2013-03-12 | 2022-04-12 | President And Fellows Of Harvard College | Method for generating a three-dimensional nucleic acid containing matrix |
US11306309B2 (en) | 2015-04-06 | 2022-04-19 | The Board Of Trustees Of The Leland Stanford Junior University | Chemically modified guide RNAs for CRISPR/CAS-mediated gene regulation |
US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
WO2022112596A1 (en) | 2020-11-30 | 2022-06-02 | Cellectis Sa | Use of aminoquinoline compounds for higher gene integration |
US11390884B2 (en) | 2015-05-11 | 2022-07-19 | Editas Medicine, Inc. | Optimized CRISPR/cas9 systems and methods for gene editing in stem cells |
US11407985B2 (en) | 2013-12-12 | 2022-08-09 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for genome editing |
US11439712B2 (en) | 2014-04-08 | 2022-09-13 | North Carolina State University | Methods and compositions for RNA-directed repression of transcription using CRISPR-associated genes |
US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11499151B2 (en) | 2017-04-28 | 2022-11-15 | Editas Medicine, Inc. | Methods and systems for analyzing guide RNA molecules |
US11542466B2 (en) | 2015-12-22 | 2023-01-03 | North Carolina State University | Methods and compositions for delivery of CRISPR based antimicrobials |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11542554B2 (en) | 2015-11-03 | 2023-01-03 | President And Fellows Of Harvard College | Method and apparatus for volumetric imaging |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
US11578312B2 (en) | 2015-06-18 | 2023-02-14 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of CAS9 orthologs and variants for sequence manipulation |
US11597924B2 (en) | 2016-03-25 | 2023-03-07 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
US11702662B2 (en) | 2011-08-26 | 2023-07-18 | Gen9, Inc. | Compositions and methods for high fidelity assembly of nucleic acids |
US11713485B2 (en) | 2016-04-25 | 2023-08-01 | President And Fellows Of Harvard College | Hybridization chain reaction methods for in situ molecular detection |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
US11884915B2 (en) | 2021-09-10 | 2024-01-30 | Agilent Technologies, Inc. | Guide RNAs with chemical modification for prime editing |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11911415B2 (en) | 2015-06-09 | 2024-02-27 | Editas Medicine, Inc. | CRISPR/Cas-related methods and compositions for improving transplantation |
US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014191518A1 (en) | 2013-05-29 | 2014-12-04 | Cellectis | A method for producing precise dna cleavage using cas9 nickase activity |
WO2017205290A1 (en) * | 2016-05-23 | 2017-11-30 | The Trustees Of Columbia University In The City Of New York | Bypassing the pam requirement of the crispr-cas system |
US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
ES2913457T3 (en) | 2017-06-30 | 2022-06-02 | Inscripta Inc | Automated Cell Processing Methods, Modules, Instruments and Systems |
WO2019156475A1 (en) * | 2018-02-06 | 2019-08-15 | 주식회사 진씨커 | Mutant cell-free dna isolation kit and mutant cell-free dna isolation method using same |
KR102086689B1 (en) * | 2018-02-06 | 2020-03-09 | 주식회사 진씨커 | Kit for isolation of mutant cell free DNA and method for isolation of mutant cell free DNA using the same |
US10858761B2 (en) | 2018-04-24 | 2020-12-08 | Inscripta, Inc. | Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells |
US10557216B2 (en) | 2018-04-24 | 2020-02-11 | Inscripta, Inc. | Automated instrumentation for production of T-cell receptor peptide libraries |
JP2022505440A (en) * | 2018-11-01 | 2022-01-14 | キージーン ナムローゼ フェンノートシャップ | Dual guide RNA for CRISPR / Cas genome editing in plant cells |
US11001831B2 (en) | 2019-03-25 | 2021-05-11 | Inscripta, Inc. | Simultaneous multiplex genome editing in yeast |
CN113939593A (en) | 2019-06-06 | 2022-01-14 | 因思科瑞普特公司 | Treatment for recursive nucleic acid-guided cell editing |
WO2021102059A1 (en) | 2019-11-19 | 2021-05-27 | Inscripta, Inc. | Methods for increasing observed editing in bacteria |
CN111004816B (en) * | 2019-11-28 | 2021-09-03 | 北京复昇生物科技有限公司 | Exogenous gene site-directed knock-in method based on Cas12a technology |
EP4069851A4 (en) | 2019-12-18 | 2023-11-22 | Inscripta, Inc. | Cascade/dcas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells |
US20210332388A1 (en) | 2020-04-24 | 2021-10-28 | Inscripta, Inc. | Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells |
WO2022060749A1 (en) | 2020-09-15 | 2022-03-24 | Inscripta, Inc. | Crispr editing to embed nucleic acid landing pads into genomes of live cells |
AU2021415461A1 (en) * | 2021-01-04 | 2023-08-17 | Inscripta, Inc. | Mad nucleases |
US11884924B2 (en) | 2021-02-16 | 2024-01-30 | Inscripta, Inc. | Dual strand nucleic acid-guided nickase editing |
EP4341391A1 (en) | 2021-05-20 | 2024-03-27 | Cellectis S.A. | Gene therapy for the treatment of hyper-ige syndrome (hies) by targeted gene integration |
WO2023039592A1 (en) * | 2021-09-13 | 2023-03-16 | Board Of Regents, The University Of Texas System | Cas9 variants with improved specificity |
JPWO2023054573A1 (en) * | 2021-09-30 | 2023-04-06 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013142578A1 (en) * | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
WO2013141680A1 (en) * | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
WO2014065596A1 (en) * | 2012-10-23 | 2014-05-01 | Toolgen Incorporated | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof |
EP3004349A1 (en) | 2013-05-29 | 2016-04-13 | Cellectis S.A. | A method for producing precise dna cleavage using cas9 nickase activity |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR201806812T4 (en) * | 2012-05-25 | 2018-06-21 | Charpentier Emmanuelle | Methods and compositions for RNA-directed target DNA modification and for RNA-directed transcription modification. |
KR102145760B1 (en) * | 2012-12-06 | 2020-08-19 | 시그마-알드리치 컴퍼니., 엘엘씨 | Crispr-based genome modification and regulation |
US20140310830A1 (en) * | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
SG10201707569YA (en) * | 2012-12-12 | 2017-10-30 | Broad Inst Inc | Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications |
EP2840140B2 (en) * | 2012-12-12 | 2023-02-22 | The Broad Institute, Inc. | Crispr-Cas based method for mutation of prokaryotic cells |
CN111454951A (en) * | 2013-03-14 | 2020-07-28 | 卡里布生物科学公司 | Compositions and methods for nucleic acid-targeted nucleic acids |
US11685935B2 (en) * | 2013-05-29 | 2023-06-27 | Cellectis | Compact scaffold of Cas9 in the type II CRISPR system |
-
2014
- 2014-05-28 WO PCT/EP2014/061178 patent/WO2014191518A1/en active Application Filing
- 2014-05-28 JP JP2016516169A patent/JP7065564B2/en active Active
- 2014-05-28 US US14/892,743 patent/US20160122774A1/en not_active Abandoned
- 2014-05-28 ES ES14727479.9T patent/ES2670531T3/en active Active
- 2014-05-28 DK DK14727479.9T patent/DK3004349T3/en active
- 2014-05-28 EP EP14727479.9A patent/EP3004349B1/en active Active
- 2014-05-28 AU AU2014273082A patent/AU2014273082B2/en active Active
- 2014-05-28 CA CA2913865A patent/CA2913865C/en active Active
-
2016
- 2016-10-11 HK HK16111735.9A patent/HK1223400A1/en unknown
-
2018
- 2018-07-25 US US16/045,602 patent/US20180327761A1/en not_active Abandoned
-
2020
- 2020-07-29 JP JP2020127886A patent/JP2021003107A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013142578A1 (en) * | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
WO2013141680A1 (en) * | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
WO2014065596A1 (en) * | 2012-10-23 | 2014-05-01 | Toolgen Incorporated | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof |
EP3004349A1 (en) | 2013-05-29 | 2016-04-13 | Cellectis S.A. | A method for producing precise dna cleavage using cas9 nickase activity |
Non-Patent Citations (20)
Title |
---|
CONG ET AL.: "Multiplex Genome Engineering Using CRISPR/Cas Systems", SCIENCE, vol. 339, no. 6121, 14 February 2013 (2013-02-14), pages 819 - 823, XP055458249 |
G. GASIUNAS ET AL: "Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 39, 25 September 2012 (2012-09-25), pages E2579 - E2586, XP055068588, ISSN: 0027-8424, DOI: 10.1073/pnas.1208507109 * |
HSU PATRICK D ET AL: "DNA targeting specificity of RNA-guided Cas9 nucleases.", NATURE BIOTECHNOLOGY SEP 2013, vol. 31, no. 9, September 2013 (2013-09-01), pages 827 - 832, XP002718604, ISSN: 1546-1696 * |
HSU PATRICK D ET AL: "Supplementary Information: DNA targeting specificity of RNA-guided Cas9 nucleases.", NATURE BIOTECHNOLOGY SEP 2013, vol. 31, no. 9, September 2013 (2013-09-01), pages 1 - 26, XP002718605, ISSN: 1546-1696 * |
J. E. DICARLO ET AL: "Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems", NUCLEIC ACIDS RESEARCH, vol. 41, no. 7, 4 March 2013 (2013-03-04), pages 4336 - 4343, XP055086617, ISSN: 0305-1048, DOI: 10.1093/nar/gkt135 * |
JIANG WENYAN ET AL: "RNA-guided editing of bacterial genomes using CRISPR-Cas systems", NATURE BIOTECHNOLOGY,, vol. 31, no. 3, 1 March 2013 (2013-03-01), pages 233 - 239, XP002699849 * |
L. CONG ET AL: "Multiplex Genome Engineering Using CRISPR/Cas Systems", SCIENCE, vol. 339, no. 6, 15 February 2013 (2013-02-15), pages 819 - 823, XP055067741 |
L. CONG ET AL: "Multiplex Genome Engineering Using CRISPR/Cas Systems", SCIENCE, vol. 339, no. 6121, 15 February 2013 (2013-02-15), pages 819 - 823, XP055067741, ISSN: 0036-8075, DOI: 10.1126/science.1231143 * |
L. CONG ET AL: "Supplementary Material to : Multiplex Genome Engineering Using CRISPR/Cas Systems", SCIENCE, vol. 339, no. 6121, 3 January 2013 (2013-01-03), pages 1 - 25, XP055067744, ISSN: 0036-8075, DOI: 10.1126/science.1231143 * |
LEI S. QI ET AL: "Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression", CELL, vol. 152, no. 5, 1 February 2013 (2013-02-01), pages 1173 - 1183, XP055068548, ISSN: 0092-8674, DOI: 10.1016/j.cell.2013.02.022 * |
M. JINEK ET AL: "A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity", SCIENCE, vol. 337, no. 6096, 17 August 2012 (2012-08-17), pages 816 - 821, XP055067740, ISSN: 0036-8075, DOI: 10.1126/science.1225829 * |
MALI PRASHANT ET AL: "Cas9 as a versatile tool for engineering biology.", NATURE METHODS OCT 2013, vol. 10, no. 10, October 2013 (2013-10-01), pages 957 - 963, XP002718606, ISSN: 1548-7105 * |
MARTIN JINEK ET AL: "RNA-programmed genome editing in human cells", E-LIFE, SAM LTD, GB, vol. 2, 29 January 2013 (2013-01-29), pages e00471 - 1, XP002699851, ISSN: 2050-084X, [retrieved on 20130628], DOI: 10.7554/ELIFE.00471 * |
P. MALI ET AL: "RNA-Guided Human Genome Engineering via Cas9", SCIENCE, vol. 339, no. 6121, 3 January 2013 (2013-01-03), pages 823 - 826, XP055111247, ISSN: 0036-8075, DOI: 10.1126/science.1232033 * |
RAN F ANN ET AL: "Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity.", CELL 12 SEP 2013, vol. 154, no. 6, 12 September 2013 (2013-09-12), pages 1380 - 1389, XP002718603, ISSN: 1097-4172 * |
RAN F ANN ET AL: "Genome engineering using the CRISPR-Cas9 system", NATURE PROTOCOLS, NATURE PUBLISHING GROUP, GB, vol. 8, no. 11, 1 November 2013 (2013-11-01), pages 2281 - 2308, XP009174668, ISSN: 1750-2799 * |
SEUNG WOO CHO ET AL: "Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 31, no. 3, 1 March 2013 (2013-03-01), pages 230 - 232, XP002699850, ISSN: 1087-0156, [retrieved on 20130129], DOI: 10.1038/NBT.2507 * |
WEI CHUANXIAN ET AL: "TALEN or Cas9 - rapid, efficient and specific choices for genome modifications.", JOURNAL OF GENETICS AND GENOMICS = YI CHUAN XUE BAO 20 JUN 2013, vol. 40, no. 6, 12 April 2013 (2013-04-12), pages 281 - 289, XP002718601, ISSN: 1673-8527 * |
WOONG Y HWANG ET AL: "Efficient genome editing in zebrafish using a CRISPR-Cas system", NATURE BIOTECHNOLOGY, vol. 31, no. 3, 29 January 2013 (2013-01-29), pages 227 - 229, XP055086625, ISSN: 1087-0156, DOI: 10.1038/nbt.2501 * |
WOONG Y HWANG ET AL: "Supplementary Material to: Efficient genome editing in zebrafish using a CRISPR-Cas system", NATURE BIOTECHNOLOGY, vol. 31, no. 3, 29 January 2013 (2013-01-29), pages 1 - 21, XP002718602, ISSN: 1087-0156, DOI: 10.1038/nbt.2501 * |
Cited By (221)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10202608B2 (en) | 2006-08-31 | 2019-02-12 | Gen9, Inc. | Iterative nucleic acid assembly using activation of vector-encoded traits |
US11845054B2 (en) | 2010-11-12 | 2023-12-19 | Gen9, Inc. | Methods and devices for nucleic acids synthesis |
US10457935B2 (en) | 2010-11-12 | 2019-10-29 | Gen9, Inc. | Protein arrays and methods of using and making the same |
US10982208B2 (en) | 2010-11-12 | 2021-04-20 | Gen9, Inc. | Protein arrays and methods of using and making the same |
US11084014B2 (en) | 2010-11-12 | 2021-08-10 | Gen9, Inc. | Methods and devices for nucleic acids synthesis |
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US9322006B2 (en) | 2011-07-22 | 2016-04-26 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US11702662B2 (en) | 2011-08-26 | 2023-07-18 | Gen9, Inc. | Compositions and methods for high fidelity assembly of nucleic acids |
US11111521B2 (en) | 2011-12-22 | 2021-09-07 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11639518B2 (en) | 2011-12-22 | 2023-05-02 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11293052B2 (en) | 2011-12-22 | 2022-04-05 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11566276B2 (en) | 2011-12-22 | 2023-01-31 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11293051B2 (en) | 2011-12-22 | 2022-04-05 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11549136B2 (en) | 2011-12-22 | 2023-01-10 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11566277B2 (en) | 2011-12-22 | 2023-01-31 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US10308931B2 (en) | 2012-03-21 | 2019-06-04 | Gen9, Inc. | Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis |
US10927369B2 (en) | 2012-04-24 | 2021-02-23 | Gen9, Inc. | Methods for sorting nucleic acids and multiplexed preparative in vitro cloning |
US10081807B2 (en) | 2012-04-24 | 2018-09-25 | Gen9, Inc. | Methods for sorting nucleic acids and multiplexed preparative in vitro cloning |
US11072789B2 (en) | 2012-06-25 | 2021-07-27 | Gen9, Inc. | Methods for nucleic acid assembly and high throughput sequencing |
US10930367B2 (en) | 2012-12-12 | 2021-02-23 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for Cas enzymes or CRISPR-Cas systems for target sequences and conveying results thereof |
US11041173B2 (en) | 2012-12-12 | 2021-06-22 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
US11299767B2 (en) | 2013-03-12 | 2022-04-12 | President And Fellows Of Harvard College | Method for generating a three-dimensional nucleic acid containing matrix |
US10385359B2 (en) | 2013-04-16 | 2019-08-20 | Regeneron Pharmaceuticals, Inc. | Targeted modification of rat genome |
US10975390B2 (en) | 2013-04-16 | 2021-04-13 | Regeneron Pharmaceuticals, Inc. | Targeted modification of rat genome |
US10767194B2 (en) | 2013-06-04 | 2020-09-08 | President And Fellows Of Harvard College | RNA-guided transcriptional regulation |
EP3003392A4 (en) * | 2013-06-04 | 2017-05-03 | President and Fellows of Harvard College | Rna-guideded transcriptional regulation |
JP2021045153A (en) * | 2013-06-04 | 2021-03-25 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Rna-guided transcriptional regulation |
JP7119055B2 (en) | 2013-06-04 | 2022-08-16 | プレジデント アンド フェローズ オブ ハーバード カレッジ | RNA-induced transcriptional regulation |
JP7036511B2 (en) | 2013-06-04 | 2022-03-15 | プレジデント アンド フェローズ オブ ハーバード カレッジ | RNA-induced transcriptional regulation |
US10640789B2 (en) | 2013-06-04 | 2020-05-05 | President And Fellows Of Harvard College | RNA-guided transcriptional regulation |
EP3603679A1 (en) * | 2013-06-04 | 2020-02-05 | President and Fellows of Harvard College | Rna-guideded transcriptional regulation |
JP2019122384A (en) * | 2013-06-04 | 2019-07-25 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Rna guided transcriptional regulation |
US10781444B2 (en) | 2013-06-17 | 2020-09-22 | The Broad Institute, Inc. | Functional genomics using CRISPR-Cas systems, compositions, methods, screens and applications thereof |
US10577630B2 (en) | 2013-06-17 | 2020-03-03 | The Broad Institute, Inc. | Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy |
US10711285B2 (en) | 2013-06-17 | 2020-07-14 | The Broad Institute, Inc. | Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation |
JP2016524472A (en) * | 2013-06-17 | 2016-08-18 | ザ・ブロード・インスティテュート・インコーポレイテッド | Delivery and use of CRISPR-Cas systems, vectors and compositions for liver targeting and therapy |
JP2016523082A (en) * | 2013-06-17 | 2016-08-08 | ザ・ブロード・インスティテュート・インコーポレイテッド | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of mitotic cells |
JP2016521995A (en) * | 2013-06-17 | 2016-07-28 | ザ・ブロード・インスティテュート・インコーポレイテッド | Delivery, use and therapeutic applications of CRISPR-Cas systems and compositions for targeting disorders and diseases using viral components |
US11008588B2 (en) | 2013-06-17 | 2021-05-18 | The Broad Institute, Inc. | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
JP2016521993A (en) * | 2013-06-17 | 2016-07-28 | ザ・ブロード・インスティテュート・インコーポレイテッド | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
JP2020063238A (en) * | 2013-06-17 | 2020-04-23 | ザ・ブロード・インスティテュート・インコーポレイテッド | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of postmitotic cells |
US10946108B2 (en) | 2013-06-17 | 2021-03-16 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using viral components |
US11597949B2 (en) | 2013-06-17 | 2023-03-07 | The Broad Institute, Inc. | Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation |
US9663782B2 (en) | 2013-07-19 | 2017-05-30 | Larix Bioscience Llc | Methods and compositions for producing double allele knock outs |
US10954548B2 (en) | 2013-08-09 | 2021-03-23 | President And Fellows Of Harvard College | Nuclease profiling system |
US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
US11920181B2 (en) | 2013-08-09 | 2024-03-05 | President And Fellows Of Harvard College | Nuclease profiling system |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US10227581B2 (en) | 2013-08-22 | 2019-03-12 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US10912833B2 (en) | 2013-09-06 | 2021-02-09 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
US10682410B2 (en) | 2013-09-06 | 2020-06-16 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US11299755B2 (en) | 2013-09-06 | 2022-04-12 | President And Fellows Of Harvard College | Switchable CAS9 nucleases and uses thereof |
US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
US9999671B2 (en) | 2013-09-06 | 2018-06-19 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US11920128B2 (en) | 2013-09-18 | 2024-03-05 | Kymab Limited | Methods, cells and organisms |
EP2877571B1 (en) | 2013-09-18 | 2018-05-30 | Kymab Limited | Methods, cells and organisms |
US11499169B2 (en) | 2013-10-30 | 2022-11-15 | North Carolina State University | Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri |
US10584358B2 (en) | 2013-10-30 | 2020-03-10 | North Carolina State University | Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri |
US10190137B2 (en) | 2013-11-07 | 2019-01-29 | Editas Medicine, Inc. | CRISPR-related methods and compositions with governing gRNAS |
US9834791B2 (en) | 2013-11-07 | 2017-12-05 | Editas Medicine, Inc. | CRISPR-related methods and compositions with governing gRNAS |
US11390887B2 (en) | 2013-11-07 | 2022-07-19 | Editas Medicine, Inc. | CRISPR-related methods and compositions with governing gRNAS |
US10640788B2 (en) | 2013-11-07 | 2020-05-05 | Editas Medicine, Inc. | CRISPR-related methods and compositions with governing gRNAs |
US11820997B2 (en) | 2013-12-11 | 2023-11-21 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
US10711280B2 (en) | 2013-12-11 | 2020-07-14 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a mouse ES cell genome |
US10208317B2 (en) | 2013-12-11 | 2019-02-19 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a mouse embryonic stem cell genome |
US9546384B2 (en) | 2013-12-11 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a mouse genome |
US9840699B2 (en) | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
US11155795B2 (en) | 2013-12-12 | 2021-10-26 | The Broad Institute, Inc. | CRISPR-Cas systems, crystal structure and uses thereof |
US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
US11591581B2 (en) | 2013-12-12 | 2023-02-28 | The Broad Institute, Inc. | Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders |
US10550372B2 (en) | 2013-12-12 | 2020-02-04 | The Broad Institute, Inc. | Systems, methods and compositions for sequence manipulation with optimized functional CRISPR-Cas systems |
US11597919B2 (en) | 2013-12-12 | 2023-03-07 | The Broad Institute Inc. | Systems, methods and compositions for sequence manipulation with optimized functional CRISPR-Cas systems |
US9068179B1 (en) | 2013-12-12 | 2015-06-30 | President And Fellows Of Harvard College | Methods for correcting presenilin point mutations |
US11407985B2 (en) | 2013-12-12 | 2022-08-09 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for genome editing |
US10851357B2 (en) | 2013-12-12 | 2020-12-01 | The Broad Institute, Inc. | Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders |
US11124782B2 (en) | 2013-12-12 | 2021-09-21 | President And Fellows Of Harvard College | Cas variants for gene editing |
US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
US10787654B2 (en) | 2014-01-24 | 2020-09-29 | North Carolina State University | Methods and compositions for sequence guiding Cas9 targeting |
US11952578B2 (en) | 2014-02-27 | 2024-04-09 | Monsanto Technology Llc | Compositions and methods for site directed genomic modification |
US11186843B2 (en) | 2014-02-27 | 2021-11-30 | Monsanto Technology Llc | Compositions and methods for site directed genomic modification |
US11566254B2 (en) | 2014-02-27 | 2023-01-31 | Monsanto Technology Llc | Compositions and methods for site directed genomic modification |
US11439712B2 (en) | 2014-04-08 | 2022-09-13 | North Carolina State University | Methods and compositions for RNA-directed repression of transcription using CRISPR-associated genes |
WO2015159087A1 (en) * | 2014-04-17 | 2015-10-22 | Green Biologics Limited | Targeted mutations |
WO2015159086A1 (en) * | 2014-04-17 | 2015-10-22 | Green Biologics Limited | Deletion mutations |
US10550396B2 (en) | 2014-04-17 | 2020-02-04 | Green Biologics Limited | Deletion mutations |
US10508271B2 (en) | 2014-04-17 | 2019-12-17 | Green Biologics Limited | Targeted mutations |
US10106820B2 (en) | 2014-06-06 | 2018-10-23 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for modifying a targeted locus |
US10294494B2 (en) | 2014-06-06 | 2019-05-21 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for modifying a targeted locus |
EP3167071A4 (en) * | 2014-07-09 | 2018-01-17 | Gen9, Inc. | Compositions and methods for site-directed dna nicking and cleaving |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US10704062B2 (en) | 2014-07-30 | 2020-07-07 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US11578343B2 (en) | 2014-07-30 | 2023-02-14 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US9970030B2 (en) | 2014-08-27 | 2018-05-15 | Caribou Biosciences, Inc. | Methods for increasing CAS9-mediated engineering efficiency |
US10450584B2 (en) | 2014-08-28 | 2019-10-22 | North Carolina State University | Cas9 proteins and guiding features for DNA targeting and genome editing |
US11753651B2 (en) | 2014-08-28 | 2023-09-12 | North Carolina State University | Cas9 proteins and guiding features for DNA targeting and genome editing |
US11680268B2 (en) | 2014-11-07 | 2023-06-20 | Editas Medicine, Inc. | Methods for improving CRISPR/Cas-mediated genome-editing |
WO2016073990A3 (en) * | 2014-11-07 | 2016-08-11 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
US11697828B2 (en) | 2014-11-21 | 2023-07-11 | Regeneran Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification using paired guide RNAs |
US10457960B2 (en) | 2014-11-21 | 2019-10-29 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification using paired guide RNAs |
US10337001B2 (en) | 2014-12-03 | 2019-07-02 | Agilent Technologies, Inc. | Guide RNA with chemical modifications |
US10900034B2 (en) | 2014-12-03 | 2021-01-26 | Agilent Technologies, Inc. | Guide RNA with chemical modifications |
US10278372B2 (en) | 2014-12-10 | 2019-05-07 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
US10993419B2 (en) | 2014-12-10 | 2021-05-04 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
US9888673B2 (en) | 2014-12-10 | 2018-02-13 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
US11234418B2 (en) | 2014-12-10 | 2022-02-01 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
US11624078B2 (en) | 2014-12-12 | 2023-04-11 | The Broad Institute, Inc. | Protected guide RNAS (pgRNAS) |
US10696986B2 (en) | 2014-12-12 | 2020-06-30 | The Board Institute, Inc. | Protected guide RNAS (PGRNAS) |
JP2017538425A (en) * | 2014-12-16 | 2017-12-28 | ダニスコ・ユーエス・インク | Fungal genome modification system and method of use |
JP2018504895A (en) * | 2014-12-16 | 2018-02-22 | ダニスコ・ユーエス・インク | Fungal genome modification system and method of use |
JP2017537647A (en) * | 2014-12-16 | 2017-12-21 | ダニスコ・ユーエス・インク | Fungal genome modification system and method of use |
WO2016154579A3 (en) * | 2015-03-26 | 2017-01-26 | Editas Medicine, Inc. | Crispr/cas-mediated gene conversion |
EP3851530A1 (en) * | 2015-03-26 | 2021-07-21 | Editas Medicine, Inc. | Crispr/cas-mediated gene conversion |
US11306309B2 (en) | 2015-04-06 | 2022-04-19 | The Board Of Trustees Of The Leland Stanford Junior University | Chemically modified guide RNAs for CRISPR/CAS-mediated gene regulation |
US11851652B2 (en) | 2015-04-06 | 2023-12-26 | The Board Of Trustees Of The Leland Stanford Junior | Compositions comprising chemically modified guide RNAs for CRISPR/Cas-mediated editing of HBB |
US11535846B2 (en) | 2015-04-06 | 2022-12-27 | The Board Of Trustees Of The Leland Stanford Junior University | Chemically modified guide RNAS for CRISPR/Cas-mediated gene regulation |
US11390884B2 (en) | 2015-05-11 | 2022-07-19 | Editas Medicine, Inc. | Optimized CRISPR/cas9 systems and methods for gene editing in stem cells |
JP2018515142A (en) * | 2015-05-15 | 2018-06-14 | ダーマコン,インコーポレイテッド. | Synthetic single guide RNA for CAS9-mediated gene editing |
US11261451B2 (en) | 2015-05-29 | 2022-03-01 | North Carolina State University | Methods for screening bacteria, archaea, algae, and yeast using CRISPR nucleic acids |
US10136649B2 (en) | 2015-05-29 | 2018-11-27 | North Carolina State University | Methods for screening bacteria, archaea, algae, and yeast using CRISPR nucleic acids |
US10793842B2 (en) | 2015-06-03 | 2020-10-06 | The Regents Of The University Of California | Cas9 variants and methods of use thereof |
US10392607B2 (en) | 2015-06-03 | 2019-08-27 | The Regents Of The University Of California | Cas9 variants and methods of use thereof |
EP3303634A4 (en) * | 2015-06-03 | 2019-03-20 | The Regents of The University of California | Cas9 variants and methods of use thereof |
US11911415B2 (en) | 2015-06-09 | 2024-02-27 | Editas Medicine, Inc. | CRISPR/Cas-related methods and compositions for improving transplantation |
US11155823B2 (en) | 2015-06-15 | 2021-10-26 | North Carolina State University | Methods and compositions for efficient delivery of nucleic acids and RNA-based antimicrobials |
US10876100B2 (en) | 2015-06-18 | 2020-12-29 | The Broad Institute, Inc. | Crispr enzyme mutations reducing off-target effects |
US10494621B2 (en) | 2015-06-18 | 2019-12-03 | The Broad Institute, Inc. | Crispr enzyme mutations reducing off-target effects |
US11578312B2 (en) | 2015-06-18 | 2023-02-14 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of CAS9 orthologs and variants for sequence manipulation |
CN107849562A (en) * | 2015-07-28 | 2018-03-27 | 丹尼斯科美国公司 | Genome editing system and application method |
WO2017019867A1 (en) * | 2015-07-28 | 2017-02-02 | Danisco Us Inc | Genome editing systems and methods of use |
US20180208945A1 (en) * | 2015-07-28 | 2018-07-26 | Danisco Us Inc. | Genome editing systems and methods of use |
US11266692B2 (en) | 2015-07-31 | 2022-03-08 | Regents Of The University Of Minnesota | Intracellular genomic transplant and methods of therapy |
US11925664B2 (en) | 2015-07-31 | 2024-03-12 | Intima Bioscience, Inc. | Intracellular genomic transplant and methods of therapy |
US10166255B2 (en) | 2015-07-31 | 2019-01-01 | Regents Of The University Of Minnesota | Intracellular genomic transplant and methods of therapy |
US10406177B2 (en) | 2015-07-31 | 2019-09-10 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
US11903966B2 (en) | 2015-07-31 | 2024-02-20 | Regents Of The University Of Minnesota | Intracellular genomic transplant and methods of therapy |
US11642375B2 (en) | 2015-07-31 | 2023-05-09 | Intima Bioscience, Inc. | Intracellular genomic transplant and methods of therapy |
US11583556B2 (en) | 2015-07-31 | 2023-02-21 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
US11642374B2 (en) | 2015-07-31 | 2023-05-09 | Intima Bioscience, Inc. | Intracellular genomic transplant and methods of therapy |
US11147837B2 (en) | 2015-07-31 | 2021-10-19 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
US11667911B2 (en) | 2015-09-24 | 2023-06-06 | Editas Medicine, Inc. | Use of exonucleases to improve CRISPR/CAS-mediated genome editing |
EP3786294A1 (en) * | 2015-09-24 | 2021-03-03 | Editas Medicine, Inc. | Use of exonucleases to improve crispr/cas-mediated genome editing |
WO2017053879A1 (en) * | 2015-09-24 | 2017-03-30 | Editas Medicine, Inc. | Use of exonucleases to improve crispr/cas-mediated genome editing |
US11286480B2 (en) | 2015-09-28 | 2022-03-29 | North Carolina State University | Methods and compositions for sequence specific antimicrobials |
US11149281B2 (en) | 2015-10-06 | 2021-10-19 | Institute For Basic Science | Method for producing genome-modified plants from plant protoplasts at high efficiency |
JP2020022455A (en) * | 2015-10-06 | 2020-02-13 | インスティチュート フォー ベーシック サイエンスInstitute For Basic Science | Method for highly efficiently producing genome-edited plant body from plant protoplast |
JP2018530348A (en) * | 2015-10-06 | 2018-10-18 | インスティチュート フォー ベーシック サイエンスInstitute For Basic Science | A highly efficient method for producing genome-editing plants from plant protoplasts |
US10167457B2 (en) | 2015-10-23 | 2019-01-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US11214780B2 (en) | 2015-10-23 | 2022-01-04 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US11542554B2 (en) | 2015-11-03 | 2023-01-03 | President And Fellows Of Harvard College | Method and apparatus for volumetric imaging |
JP2022081503A (en) * | 2015-11-23 | 2022-05-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9 |
JP2019500899A (en) * | 2015-11-23 | 2019-01-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Cellular RNA tracking and manipulation through nuclear delivery of CRISPR / Cas9 |
US11667903B2 (en) | 2015-11-23 | 2023-06-06 | The Regents Of The University Of California | Tracking and manipulating cellular RNA via nuclear delivery of CRISPR/CAS9 |
US11542466B2 (en) | 2015-12-22 | 2023-01-03 | North Carolina State University | Methods and compositions for delivery of CRISPR based antimicrobials |
WO2017118720A1 (en) * | 2016-01-08 | 2017-07-13 | Novozymes A/S | Genome editing in bacillus host cells |
EP3219799A1 (en) | 2016-03-17 | 2017-09-20 | IMBA-Institut für Molekulare Biotechnologie GmbH | Conditional crispr sgrna expression |
WO2017158153A1 (en) | 2016-03-17 | 2017-09-21 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Conditional crispr sgrna expression |
US11597924B2 (en) | 2016-03-25 | 2023-03-07 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
US11236313B2 (en) | 2016-04-13 | 2022-02-01 | Editas Medicine, Inc. | Cas9 fusion molecules, gene editing systems, and methods of use thereof |
WO2017186718A1 (en) * | 2016-04-25 | 2017-11-02 | Universität Basel | Allele editing and applications thereof |
US11713485B2 (en) | 2016-04-25 | 2023-08-01 | President And Fellows Of Harvard College | Hybridization chain reaction methods for in situ molecular detection |
US10266851B2 (en) | 2016-06-02 | 2019-04-23 | Sigma-Aldrich Co. Llc | Using programmable DNA binding proteins to enhance targeted genome modification |
EP3604527A1 (en) * | 2016-06-02 | 2020-02-05 | Sigma Aldrich Co. LLC | Using programmable dna binding proteins to enhance targeted genome modification |
EP3907286A1 (en) * | 2016-06-02 | 2021-11-10 | Sigma-Aldrich Co., LLC | Using programmable dna binding proteins to enhance targeted genome modification |
KR102458395B1 (en) | 2016-06-02 | 2022-10-25 | 시그마-알드리치 컴퍼니., 엘엘씨 | Improvement of Targeted Genomic Modifications Using Programmable DNA Binding Proteins |
KR20190025565A (en) * | 2016-06-02 | 2019-03-11 | 시그마-알드리치 컴퍼니., 엘엘씨 | Improvement of targeted genomic modification using a programmable DNA binding protein |
EP3272867A1 (en) * | 2016-06-02 | 2018-01-24 | Sigma-Aldrich Co. LLC | Using programmable dna binding proteins to enhance targeted genome modification |
US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
WO2018015444A1 (en) * | 2016-07-22 | 2018-01-25 | Novozymes A/S | Crispr-cas9 genome editing with multiple guide rnas in filamentous fungi |
US11912987B2 (en) | 2016-08-03 | 2024-02-27 | KSQ Therapeutics, Inc. | Methods for screening for cancer targets |
US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US11702651B2 (en) | 2016-08-03 | 2023-07-18 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US10947530B2 (en) | 2016-08-03 | 2021-03-16 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US11078481B1 (en) | 2016-08-03 | 2021-08-03 | KSQ Therapeutics, Inc. | Methods for screening for cancer targets |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11078483B1 (en) | 2016-09-02 | 2021-08-03 | KSQ Therapeutics, Inc. | Methods for measuring and improving CRISPR reagent function |
US11946163B2 (en) | 2016-09-02 | 2024-04-02 | KSQ Therapeutics, Inc. | Methods for measuring and improving CRISPR reagent function |
WO2018054911A1 (en) | 2016-09-23 | 2018-03-29 | Bayer Cropscience Nv | Targeted genome optimization in plants |
US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
US11154574B2 (en) | 2016-10-18 | 2021-10-26 | Regents Of The University Of Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
US10912797B2 (en) | 2016-10-18 | 2021-02-09 | Intima Bioscience, Inc. | Tumor infiltrating lymphocytes and methods of therapy |
WO2018083461A1 (en) * | 2016-11-01 | 2018-05-11 | Auxolytic Ltd | Regulatable cell lines and methods of use thereof |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
US11820969B2 (en) | 2016-12-23 | 2023-11-21 | President And Fellows Of Harvard College | Editing of CCR2 receptor gene to protect against HIV infection |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
US11499151B2 (en) | 2017-04-28 | 2022-11-15 | Editas Medicine, Inc. | Methods and systems for analyzing guide RNA molecules |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
US10428319B2 (en) | 2017-06-09 | 2019-10-01 | Editas Medicine, Inc. | Engineered Cas9 nucleases |
US11098297B2 (en) | 2017-06-09 | 2021-08-24 | Editas Medicine, Inc. | Engineered Cas9 nucleases |
US11098325B2 (en) | 2017-06-30 | 2021-08-24 | Intima Bioscience, Inc. | Adeno-associated viral vectors for gene therapy |
US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11932884B2 (en) | 2017-08-30 | 2024-03-19 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
WO2019138083A1 (en) | 2018-01-12 | 2019-07-18 | Basf Se | Gene underlying the number of spikelets per spike qtl in wheat on chromosome 7a |
WO2019217803A1 (en) | 2018-05-10 | 2019-11-14 | Auxolytic Ltd. | Gene therapy methods and compositions using auxotrophic regulatable cells |
US10711267B2 (en) | 2018-10-01 | 2020-07-14 | North Carolina State University | Recombinant type I CRISPR-Cas system |
US11680259B2 (en) | 2018-10-01 | 2023-06-20 | North Carolina State University | Recombinant type I CRISPR-CAS system |
WO2020128478A1 (en) | 2018-12-19 | 2020-06-25 | King's College London | Immunotherapeutic methods and compositions |
US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11795452B2 (en) | 2019-03-19 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11643652B2 (en) | 2019-03-19 | 2023-05-09 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
WO2021122080A1 (en) * | 2019-12-16 | 2021-06-24 | BASF Agricultural Solutions Seed US LLC | Improved genome editing using paired nickases |
US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
WO2021239758A1 (en) * | 2020-05-27 | 2021-12-02 | Snipr Biome Aps. | Multiplex crispr/cas system for modifying cell genomes |
FR3110916A1 (en) * | 2020-05-27 | 2021-12-03 | Snipr Biome Aps | PRODUCTS & METHODS |
WO2022112596A1 (en) | 2020-11-30 | 2022-06-02 | Cellectis Sa | Use of aminoquinoline compounds for higher gene integration |
US11884915B2 (en) | 2021-09-10 | 2024-01-30 | Agilent Technologies, Inc. | Guide RNAs with chemical modification for prime editing |
Also Published As
Publication number | Publication date |
---|---|
JP2016520317A (en) | 2016-07-14 |
HK1223400A1 (en) | 2017-07-28 |
CA2913865A1 (en) | 2014-12-04 |
EP3004349B1 (en) | 2018-03-28 |
US20180327761A1 (en) | 2018-11-15 |
CA2913865C (en) | 2022-07-19 |
AU2014273082A1 (en) | 2015-12-17 |
DK3004349T3 (en) | 2018-06-06 |
JP7065564B2 (en) | 2022-05-12 |
AU2014273082B2 (en) | 2018-11-08 |
JP2021003107A (en) | 2021-01-14 |
EP3004349A1 (en) | 2016-04-13 |
ES2670531T3 (en) | 2018-05-30 |
US20160122774A1 (en) | 2016-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180327761A1 (en) | Method for producing precise dna cleavage using cas9 nickase activity | |
AU2014273085B2 (en) | New compact scaffold of Cas9 in the type II CRISPR system | |
AU2014338910B2 (en) | Design of rare-cutting endonucleases for efficient and specific targeting DNA sequences comprising highly repetitive motives | |
EP2633040B1 (en) | Method for increasing the efficiency of double-strand break-induced mutagenesis | |
EP2828384B1 (en) | Method to overcome dna chemical modifications sensitivity of engineered tale dna binding domains | |
EP2825190B1 (en) | Repeat variable diresidues for targeting nucleotides | |
WO2014102688A1 (en) | New design matrix for improvement of homology-directed gene targeting | |
EP2951295B1 (en) | Tevi chimeric endonucleases and their preferential cleavage sites | |
Class et al. | Patent application title: A METHOD FOR PRODUCING PRECISE DNA CLEAVAGE USING CAS9 NICKASE ACTIVITY Inventors: Philippe Duchateau (Draveil, FR) Philippe Duchateau (Draveil, FR) Claudia Bertonati (Paris, FR) | |
Class et al. | Patent application title: NEW COMPACT SCAFFOLD OF CAS9 IN THE TYPE II CRISPR SYSTEM Inventors: Philippe Duchateau (Draveil, FR) Philippe Duchateau (Draveil, FR) Claudia Bertonati (Paris, FR) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14727479 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14892743 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2913865 Country of ref document: CA Ref document number: 2016516169 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2014273082 Country of ref document: AU Date of ref document: 20140528 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014727479 Country of ref document: EP |